Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

TACTIVE-U: En undersøgelse for at lære om undersøgelsesmedicinen (Vepdegestrant), når den gives sammen med anden medicin hos mennesker med avanceret eller metastatisk brystkræft. (Delstudie C)

23. oktober 2026 opdateret af: Pfizer

TACTIVE-U: EN INTERVENTIONEL SIKKERHED OG EFFEKTIVITET FASE 1B/2, ÅBEN LABEL PARAPLYSTUDIE TIL UNDERSØGELSE AF TOLERABILITET, PK OG ANTITUMOR AKTIVITET HOS VEPDEGESTRAND (ARV-471/PF-07850327) DEN ANDEN ANTICANCERBEHANDLINGER HOS DELTAGERE PÅ 18 ÅR OG OVER MED ER+ AVANCERET ELLER METASTATISK BRYSTCANCER, DELUNDERSØGELSE C (ARV-471 I KOMBINATION MED SAMURACICLIB)

The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat.

The study is seeking for participants who have breast cancer that:

  • is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive).
  • is no longer responding to treatments taken before starting this study.

This study is divided into separate sub-studies.

For Sub-Study C:

All the participants will receive vepdegestrant and a medicine called samuraciclib.

Vepdegestrant and samuraciclib will be taken once in a day by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicine is safe and effective.

Participant will continue to take vepdegestrant and samuraciclib until:

  • their cancer is no longer responding, or
  • side effects become too severe.

They will have visits at the study clinic about every 4 weeks.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

C4891024 is a prospective, open-label, multicenter, Phase 1b/2 sub-study to evaluate the safety, antitumor activity, and PK of ARV-471 with samuraciclib in the treatment of participants with A/MBC. The sub-study is part of Umbrella platform, TACTIVE-U, comprising multiple sub-studies that independently evaluate ARV-471 in participants with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer. ARV-471 will act as the backbone therapy given in combination with other anticancer agents thought to have clinical relevance in ER+ breast cancer.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

11

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Bruxelles-capitale, Région de
      • Anderlecht, Bruxelles-capitale, Région de, Belgien, 1070
        • Institut Jules Bordet
    • Arkansas
      • Fayetteville, Arkansas, Forenede Stater, 72703
        • Highlands Oncology Group
      • Rogers, Arkansas, Forenede Stater, 72758
        • Highlands Oncology Group
      • Springdale, Arkansas, Forenede Stater, 72762
        • Highlands Oncology Group
    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford Women's Cancer Center
      • Palo Alto, California, Forenede Stater, 94304
        • Clinical and Translational Research Unit (CTRU)
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford Cancer Institute - Clinical Trials Office
    • Colorado
      • Fort Collins, Colorado, Forenede Stater, 80524
        • UCHealth Poudre Valley Hospital
      • Fort Collins, Colorado, Forenede Stater, 80528
        • UCHealth Harmony
      • Greeley, Colorado, Forenede Stater, 80634
        • UCHealth Greeley Hospital
      • Loveland, Colorado, Forenede Stater, 80538
        • UCHealth - Medical Center of the Rockies
    • Illinois
      • Shiloh, Illinois, Forenede Stater, 62269
        • Memorial Hospital East
      • Shiloh, Illinois, Forenede Stater, 62269
        • Siteman Cancer Center - Shiloh
    • Missouri
      • City of Saint Peters, Missouri, Forenede Stater, 63376
        • Siteman Cancer Center - St Peters
      • Creve Coeur, Missouri, Forenede Stater, 63141
        • Siteman Cancer Center - West County
      • Florissant, Missouri, Forenede Stater, 63031
        • Siteman Cancer Center - North County
      • St Louis, Missouri, Forenede Stater, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine - Siteman Cancer Center
      • St Louis, Missouri, Forenede Stater, 63129
        • Siteman Cancer Center - South County
    • Côte-d'or
      • Dijon, Côte-d'or, Frankrig, 21079
        • Centre Georges François Leclerc
      • Roma, Italien, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    • Lombardy
      • Monza, Lombardy, Italien, 20900
        • Fondazione IRCCS San Gerardo dei Tintori

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histological or cytological diagnosis of breast cancer. At time of enrollment this must not be amendable to surgical resection with curative intent (≥1% ER+ stained cells as per local practice on the most recent tumor biopsy HER2- tumor by IHC or in-situ hybridization per ASCO/CAP).
  • prior anticancer therapies: up to 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (in any setting eg adjuvant, metastatic)
  • at least 1 measurable lesion as defined by RECIST v1.1.
  • ECOG PS ≤1.

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term
  • known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
  • newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 28 days prior to enrollment in the of study.
  • history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
  • inflammatory breast cancer
  • impaired cardiovascular function or clinically significant cardiovascular diseases
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors/inducers of CYP3A, strong CYP2D6 inhibitors and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function
  • known active infection

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ARV-471 in combination with Samuraciclib

ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles

Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Andre navne:
  • ARV-471 / PF-07850327

Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1b: Number of Participants With Dose Limiting Toxicities
Tidsramme: 28 days

Dose Limiting Toxicities rate for ARV-471 in combination with Samuraciclib, estimated based on data from DLT-evaluable participants during the DLT observation period (Cycle 1).

28 days
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Tidsramme: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

Steady-state Area under the plasma concentration versus time curve (AUCtau) of ARV-471 with and without coadministration of samuraciclib

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Tidsramme: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)

Steady-state Peak Plasma concentration ( Cmax) of ARV-471 with and without coadministration of samuraciclib

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Phase 2: Percentage of Participants With Objective Response by investigator assessment
Tidsramme: Up to approximately 1 year

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

Up to approximately 1 year
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Tidsramme: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Single dose AUC0-72 of samuraciclib with and without coadministration of ARV 471.

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Tidsramme: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Single dose Cmax of samuraciclib with and without coadministration of ARV 471.

From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1b, Drug drug interaction and Phase 2: Evaluation of Safety and Tolerability of ARV-471 in combination with Samuraciclib
Tidsramme: First study drug dose through a minimum of 28 Days After Last study drug administration

AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to ARV-471 in combination with samuraciclib.

Laboratory test abnormalities as characterized by type, frequency, intensity (as graded by NCI CTCAE version 5.0), and timing.

Changes from baseline for the ECG parameters heart rate, QTcF, PR interval, and QRS complex will be summarized by treatment and time. The frequency of uncorrected QT values above 500 ms will be tabulated.

First study drug dose through a minimum of 28 Days After Last study drug administration
Phase 1b: To evaluate antitumor activity of ARV-471 in combination with samuraciclib
Tidsramme: Up to approximately 1 year

Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

Up to approximately 1 year
Phase 1b and Phase 2: Duration of Response by investigator assessment.
Tidsramme: Up to approximately 1 year

Duration of Response (DoR) is defined for participants with confirmed OR (CR or PR) as the time from the first documentation of OR to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Up to approximately 1 year
Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.
Tidsramme: Up to approximately 1 year

Clinical Benefit Response (CBR) is defined as the proportion of participants with Best Overall Response of confirmed CR or PR at any time, or Stable Disease (SD) ≥24 weeks

Up to approximately 1 year
Phase 1b and Phase 2: Progression Free Survival by investigator assessment.
Tidsramme: Up to approximately 1 year

Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.

Up to approximately 1 year
Phase 1b and Phase 2: Plasma concentrations of ARV-471 and samuraciclib.
Tidsramme: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

To evaluate the plasma exposure of ARV-471 and samuraciclib when ARV-471 and samuraciclib are given in combination.

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Tidsramme: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

AUCtau of ARV-471 with and without co-administration of samuraciclib

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Tidsramme: At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)

Cmax of ARV-471 with and without co-administration of samuraciclib

At predefined intervals throughout the treatment period, up to cycle 7 (each cycle is 28 days)
Phase 2:ctDNA plasma quantitative changes from pre-treatment
Tidsramme: At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment

To assess changes from baseline levels in plasma ctDNA with treatment and to evaluate potential predictability of their associations with clinical outcomes.

At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment
Phase 2: To evaluate the correlation between TP53 mutation status and antitumor activity
Tidsramme: Screening

Participants classified on basis of pathological TP53 mutation detected or not detected.

Screening
Phase 2: Overall Survival
Tidsramme: Through study completion, up to approximately 3 year

Overall Survival (OS) is defined as the time from the date of first dose of study interventions to the date of death due to any cause

Through study completion, up to approximately 3 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. januar 2024

Primær færdiggørelse (Faktiske)

10. september 2026

Studieafslutning (Faktiske)

10. september 2026

Datoer for studieregistrering

Først indsendt

16. oktober 2023

Først indsendt, der opfyldte QC-kriterier

4. november 2023

Først opslået (Faktiske)

9. november 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

27. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • C4891024
  • 2023-507125-41-00 (Registry Identifier: CTIS (EU))
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner